Goal 2: Reduce Human Disease

Submitted by (@nhlbiforumadministrator1)

Patient-Specific Blueprints to Guide Cardiac Surgery

In order to increase the success of robotic mitral valve repair, we need to stimulate a fusion of multi-modal functional imaging with 3-D valve models that can accurately predict valve shape and closure throughout the cardiac cycle, then develop surgical “blueprints” that overlay incision and suture maps on the surgeon’s console to guide perioperative robotic repair.

Voting

-19 net votes
6 up votes
25 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@efimov)

NHLBI Cardiovascular Engineering Strategy

Most impressive and impactful advances in CV diagnostics and therapies came in the last 50 years from CV engineering, including implantable devices and imaging technology. CV engineers are developing next breakthrough technology including tissue engineering and flexible electronics. However, organizational structure of NIH does not have an entity responsible for strategic development of CV engineering. NIBIB does not ...more »

Voting

8 net votes
17 up votes
9 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@nhlbiforumadministrator)

Heart transplant surveillance

It is essential to develop clinically viable, non-invasive, less expensive technologies for the surveillance of allograft rejection in heart transplant patients. Critical challenges that exist in the near term or long term surveillance after transplant is the unavailability of molecular and cellular level markers that can be non-invasively imaged and quantified detect rejection and thus improve patient survival. Development ...more »

Voting

1 net vote
14 up votes
13 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@rezanezafat)

What do we know about Heart Failure with Preserved Ejection Fraction (HFpEF)

Mortality is similar between HFpEF and HFrEF but we have currently no viable therapeutic option for HFpEF. There have been many large trials, but they all failed. Our basic understanding of the disease is very limited which contributed to failures of many prior trials and wasting $$$. We know very little about the pathophysiology of the disease . It is time to get back to the basic science and use our new tools (e.g. ...more »

Voting

6 net votes
17 up votes
11 down votes
Active